Neutralization of inhibitory pathways in lymphocytes
US10711063B2 · kind B2 · utility
7Cited by
10References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2015 |
| Grant date | Jul 14, 2020 |
| Priority date | — |
| Expiry date | Sep 27, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.